Mark J Aronson, DO Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 85 Spring St, Laconia, NH 03246 Phone: 603-527-2969 Fax: 603-527-2858 |
Joanie Peter, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 80 High St, Laconia, NH 03246 Phone: 603-527-2819 |
Xi Nuo Gao, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 80 Highland St, Laconia, NH 03246 Phone: 603-524-3211 |
Bassem Azkul, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 22 Strafford St, Laconia, NH 03246 Phone: 603-366-1070 Fax: 603-366-1071 |
James H Clifford, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 85 Spring St, Laconia, NH 03246 Phone: 603-527-7114 Fax: 603-527-2945 |
News Archive
Between 17-21 October 2009, the 39th annual conference of the Society of Neuroscience drew some 30,500 people to the great city of Chicago, which was more balmy than windy for the occasion. Your Alzforum reporters have been busy roaming the halls, buttonholing scientists for their comments on the presentations, and putting together reports on the most significant advances.
A recent guideline for using statins to reduce atherosclerotic cardiovascular disease has wavered too far from the simple cholesterol goals that have saved thousands of lives in the past decade, and doesn't adequately treat patients as individuals, experts said today in a national report.
An innovative experimental treatment for boosting the effectiveness of stem-cell transplants with umbilical cord blood has a favorable safety profile in long-term animal studies, report scientists from Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, and Children's Hospital Boston.
Exactech, Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the acquisition of several innovative spine product lines and all related technology from VertiFlex, Inc. a leading developer of minimally invasive and motion preserving spinal surgery technologies.
t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the FDA has granted orphan drug designation to t2c001 for the treatment of Buerger's Disease. The Company also announced that in a concurrent application in Europe the EMA's Committee for Orphan Medicinal Products recently recommended t2c001 for orphan designation to the European Commission.
› Verified 5 days ago